Insmed Inc. (INSM)
Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed: Poised For Transformation Beyond ARIKAYCE
Insmed's future hinges on the development and launch of its pipeline, particularly brensocatib, despite current financial losses due to strategic investments. Brensocatib shows promising Phase 3 results for non-cystic fibrosis bronchiectasis, with a potential FDA approval by August 2025, highlighting a significant market opportunity. Insmed's diversified pipeline, including TPIP and INS1201, reduces reliance on a single product and enhances long-term growth prospects.
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says
RBC Capital Markets has initiated coverage on Insmed Inc INSM, citing brensocatib's launch momentum.
International Markets and Insmed (INSM): A Deep Dive for Investors
Examine Insmed's (INSM) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to loss of $1.28 per share a year ago.
Countdown to Insmed (INSM) Q4 Earnings: Wall Street Forecasts for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity
Insmed's Arikayce, a treatment for MAC and NTM lung diseases, generated $93.4m in Q3 2023, with full-year revenue guidance of $340m-$360m. Brensocatib, Insmed's lead pipeline candidate for non-CF bronchiectasis, received FDA Priority Review with a target action date of August 12, 2025. This is a potential multi-billion dollar selling asset. Brensocatib's market potential is significant, with Wall Street analysts projecting peak annual revenues exceeding $5bn, bolstering Insmed's market cap of $14.45bn.
Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review
The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.
